HCV Treatment
AASLD 2014: Sofosbuvir + GS-5816 for 12 Weeks Shows High Cure Rates, 8 Weeks Less Effective
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 18 November 2014 00:00
- Written by Liz Highleyman
A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to Phase 2 study findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration to 8 weeks resulted in lower efficacy for people with HCV genotypes 1 and 2, though genotype 3 patients still showed high response rates.
AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected
- Details
- Category: Approved HCV Drugs
- Published on Thursday, 13 November 2014 00:00
- Written by Liz Highleyman
An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response rates for treatment-naive and treatment-experienced genotype 1 hepatitis C patients, including people with liver cirrhosis and HIV/HCV coinfection, according to research presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston and published simultaeously in The Lancet. However, pushing treatment duration with this combination plus sofosbuvir down to 4 or 6 weeks raised the risk of treatment failure.
AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 2D Cure Most People with HCV Genotype 4
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 12 November 2014 00:00
- Written by Liz Highleyman
Sofosbuvir/ledipasvir (Harvoni) without ribavirin and AbbVie's 2D regimen (paritaprevir/ritonavir/ombitasvir) both produced high sustained virological response rates for patients with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 12 November 2014 00:00
- Written by Liz Highleyman
An oral regimen of sofosbuvir/ledipasvir (Harvoni) plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Sustained response was associated with improved liver function in most patients.
AASLD 2014: Daclatasvir TRIO Regimen Has Good Cure Rates With or Without Cirrhosis
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 11 November 2014 00:00
- Written by Liz Highleyman
A 12-week oral regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin, cured 86% to 90% of genotype 1 hepatitis C patients with cirrhosis in the Phase 3 UNITY-2 trial, while the TRIO regimen without ribavirin demonstrated similar sustained response rates for non-cirrhotics in UNITY-1, according to 2 late-breaking reports presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Findings suggest that ribavirin is still useful for some harder-to-treat patients.
More Articles...
- AASLD 2014: Sustained Response to HCV Treatment Reduces Mortality, Liver Cancer, Liver Transplants
- AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients
- FDA Approves Simeprevir + Sofosbuvir Combination for Hepatitis C
- AASLD Liver Meeting Starts this Weekend in Boston
Web Design and Development by